Payment overview · 2025
General Payments
$33.04
2 reported records · 2 companies
Healthcare provider profile · identity verified
Robert John Madden, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROME, GA · NPI 1023224151
Verified facts
What the public records show
CMS Open Payments records show Robert John Madden, MD received $33.04 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.91 | 51.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.13 | 48.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.04 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 588 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 135 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 369 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 68 |
| Omeprazole | Omeprazole | 220 | 61 |
| Tramadol Hcl | Tramadol Hcl | 204 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 61 |
| Lisinopril | Lisinopril | 188 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 43 |
| Potassium Chloride | Potassium Chloride | 156 | 44 |
| Simvastatin | Simvastatin | 156 | 43 |
| Metformin Hcl | Metformin Hcl | 145 | 43 |
| Gabapentin | Gabapentin | 141 | 39 |
| Furosemide | Furosemide | 140 | 43 |
| Azithromycin | Azithromycin | 136 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 36 |
| Famotidine | Famotidine | 126 | 37 |
| Losartan Potassium | Losartan Potassium | 122 | 36 |
| Pregabalin | Pregabalin | 117 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 31 |
| Eliquis | Apixaban | 114 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 23 |
| Clonazepam | Clonazepam | 103 | 13 |
| Meloxicam | Meloxicam | 101 | 24 |
| Atenolol | Atenolol | 91 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 13 |
| Clonidine Hcl | Clonidine Hcl | 74 | 17 |
| Glimepiride | Glimepiride | 72 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 20 |
| Ezetimibe | Ezetimibe | 63 | 22 |
| Trazodone Hcl | Trazodone Hcl | 63 | 19 |
| Ondansetron Odt | Ondansetron | 62 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 16 |
| Carvedilol | Carvedilol | 55 | 19 |
| Ozempic | Semaglutide | 55 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 15 |
| Amoxicillin | Amoxicillin | 51 | 40 |
| Benazepril Hcl | Benazepril Hcl | 50 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 32 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Carisoprodol | Carisoprodol | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 13 |
| Estradiol | Estradiol | 41 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 15 |
| Montelukast Sodium | Montelukast Sodium | 39 | 14 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 15 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Prednisone | Prednisone | 29 | 12 |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Propylthiouracil | Propylthiouracil | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.04 · 2 records | Lilly USA, LLC | MOUNJARO, PAXLOVID, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error